CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Bristol-Myers Squibb Company v. Mylan Pharmaceuticals, Inc.

1:15-cv-00049

Overview

Case Number 1:15-cv-00049
Filing Date 2015-03-19
Status Terminated
Termination Date 2015-10-26
Court District Court, N.D. West Virginia (wvnd)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Mylan Pharmaceuticals, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Bristol-Myers Squibb Company NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, N.D. West Virginia (wvnd)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 2 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 2 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (2): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (2 found):
U.S. Courts: 2
U.S. District Court 2016-02-11
1:16-cv-00074

Bristol-Myers Squibb Company v. Cipla USA, Inc.

Asserted Patent
Status: DED
U.S. District Court 2010-04-01
1:10-cv-00264

Bristol-Myers Squibb Company v. Teva Pharmaceuticals USA Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6087383
Bisulfate salt of HIV protease inhibitor
Filed: 1998-12-21
Issued: 2000-07-11
Expired (Term Ended)
Expires: 2018-12-21

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

10

Dispositive

0

Granted

3

Denied

0

Pending / Review

7

Motions by Category

Procedural / Extension Motion 10

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
MOTION for Leave to Appear Pro Hac Vice by Mylan Pharmaceuticals, Inc.. (Attachments: # 1 Text of Proposed Order)(Kennedy, E.) (Entered: 05/18/2015)
Entry #17 • 2015-05-18 Document →
Procedural / Extension Motion Pending / Under Review
MOTION for Leave to Appear Pro Hac Vice by Mylan Pharmaceuticals, Inc.. (Attachments: # 1 Text of Proposed Order)(Kennedy, E.) (Entered: 05/18/2015)
Entry #18 • 2015-05-18 Document →
Procedural / Extension Motion Pending / Under Review
MOTION for Leave to Appear Pro Hac Vice by Mylan Pharmaceuticals, Inc.. (Attachments: # 1 Text of Proposed Order)(Kennedy, E.) (Entered: 05/18/2015)
Entry #19 • 2015-05-18 Document →
Procedural / Extension Motion Pending / Under Review
CERTIFICATE OF SERVICE by Mylan Pharmaceuticals, Inc. re 18 MOTION for Leave to Appear Pro Hac Vice, 17 MOTION for Leave to Appear Pro Hac Vice, 19 MOTION for L...
Entry #20 • 2015-05-18 Document →
Procedural / Extension Motion Pending / Under Review
MOTION for Extension of Time to File Answer re 12 Answer to Complaint, Counterclaim (Unopposed) by Bristol-Myers Squibb Company. (Attachments: # 1 Text of Propo...
Entry #15 • 2015-05-15 Document →
Procedural / Extension Motion Granted
ORDER GRANTING MOTION TO EXTEND DEADLINE: it is ORDERED that Plaintiff's 15 Motion for Extension of Time to Answer re 12 Answer to Complaint, Counterclaim is he...
Entry #16 • 2015-05-15 Document →

Docket Entries

(20 total)
Pleading / Complaint

COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Bristol-Myers Squibb Company. (Attachments: # 1 Exhibit A - US Patent 6,087,383, # 2 Civil Cover Sheet)(cnd) (Entered: 03/19/2015)

Entry #1 • 2015-03-19
1

Corporate Disclosure Statement by Bristol-Myers Squibb Company. (cnd) (Entered: 03/19/2015)

Entry #2 • 2015-03-19
1
Pleading / Complaint

REPORT to USPTO on the filing or determination of an action regarding re 1 Complaint. (cnd) (Entered: 03/19/2015)

Entry #3 • 2015-03-19
1
Pleading / Complaint

SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA) re 1 Complaint filed by Bristol-Myers Squibb Company. (cnd) (Entered: 03/19/2015)

Entry #4 • 2015-03-19
1
Pleading / Complaint

VERIFICATION OF ATTORNEY ADMISSION as to Amy Wigmore and Tracey Allen re 1 Complaint. (cnd) (Entered: 03/19/2015)

Entry #5 • 2015-03-19
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc